Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up

R. Houston Thompson, Susan M. Kuntz, Bradley C. Leibovich, Haidong M Dong, Christine M. Lohse, W. Scott Webster, Shomik Sengupta, Igor Frank, Alexander Parker, Horst Zincke, Michael L. Blute, Thomas J. Sebo, John C. Cheville, Eugene D Kwon

Research output: Contribution to journalArticle

592 Citations (Scopus)

Abstract

B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor.

Original languageEnglish (US)
Pages (from-to)3381-3385
Number of pages5
JournalCancer Research
Volume66
Issue number7
DOIs
StatePublished - Apr 1 2006

Fingerprint

Renal Cell Carcinoma
Neoplasms
Odds Ratio
Mortality
Nephrectomy
Paraffin
Immunity
Survival Rate
Immunohistochemistry
Neoplasm Metastasis
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. / Thompson, R. Houston; Kuntz, Susan M.; Leibovich, Bradley C.; Dong, Haidong M; Lohse, Christine M.; Webster, W. Scott; Sengupta, Shomik; Frank, Igor; Parker, Alexander; Zincke, Horst; Blute, Michael L.; Sebo, Thomas J.; Cheville, John C.; Kwon, Eugene D.

In: Cancer Research, Vol. 66, No. 7, 01.04.2006, p. 3381-3385.

Research output: Contribution to journalArticle

Thompson, RH, Kuntz, SM, Leibovich, BC, Dong, HM, Lohse, CM, Webster, WS, Sengupta, S, Frank, I, Parker, A, Zincke, H, Blute, ML, Sebo, TJ, Cheville, JC & Kwon, ED 2006, 'Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up', Cancer Research, vol. 66, no. 7, pp. 3381-3385. https://doi.org/10.1158/0008-5472.CAN-05-4303
Thompson, R. Houston ; Kuntz, Susan M. ; Leibovich, Bradley C. ; Dong, Haidong M ; Lohse, Christine M. ; Webster, W. Scott ; Sengupta, Shomik ; Frank, Igor ; Parker, Alexander ; Zincke, Horst ; Blute, Michael L. ; Sebo, Thomas J. ; Cheville, John C. ; Kwon, Eugene D. / Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. In: Cancer Research. 2006 ; Vol. 66, No. 7. pp. 3381-3385.
@article{ec97eefb9cf54985adf206b45846c902,
title = "Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up",
abstract = "B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9{\%}) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9{\%} and 82.9{\%} for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor.",
author = "Thompson, {R. Houston} and Kuntz, {Susan M.} and Leibovich, {Bradley C.} and Dong, {Haidong M} and Lohse, {Christine M.} and Webster, {W. Scott} and Shomik Sengupta and Igor Frank and Alexander Parker and Horst Zincke and Blute, {Michael L.} and Sebo, {Thomas J.} and Cheville, {John C.} and Kwon, {Eugene D}",
year = "2006",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-05-4303",
language = "English (US)",
volume = "66",
pages = "3381--3385",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up

AU - Thompson, R. Houston

AU - Kuntz, Susan M.

AU - Leibovich, Bradley C.

AU - Dong, Haidong M

AU - Lohse, Christine M.

AU - Webster, W. Scott

AU - Sengupta, Shomik

AU - Frank, Igor

AU - Parker, Alexander

AU - Zincke, Horst

AU - Blute, Michael L.

AU - Sebo, Thomas J.

AU - Cheville, John C.

AU - Kwon, Eugene D

PY - 2006/4/1

Y1 - 2006/4/1

N2 - B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor.

AB - B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor.

UR - http://www.scopus.com/inward/record.url?scp=33645736792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645736792&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4303

DO - 10.1158/0008-5472.CAN-05-4303

M3 - Article

C2 - 16585157

AN - SCOPUS:33645736792

VL - 66

SP - 3381

EP - 3385

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -